Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...

Descripción completa

Detalles Bibliográficos
Autores principales: Darici, Salihanur, Alkhaldi, Hazem, Horne, Gillian, Jørgensen, Heather G., Marmiroli, Sandra, Huang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563273/
https://www.ncbi.nlm.nih.gov/pubmed/32932888
http://dx.doi.org/10.3390/jcm9092934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563273/
https://www.ncbi.nlm.nih.gov/pubmed/32932888
http://dx.doi.org/10.3390/jcm9092934

Ejemplares similares